ARTICLE | Emerging Company Profile
SNIPR: Turning CRISPR into a microbiome suicide
Occupying the intersection of the microbiome and CRISPR, SNIPR treats disease by using gene editing to alter gut bacterial populations
May 16, 2019 11:45 PM UTC
SNIPR is using CRISPR to target specific bacteria to fight infection or modulate the immune system.
Growing interest in CRISPR for mammalian cells and microbiome-focused therapeutics led the company's co-founders, Christian Grøndahl, Morten Sommer and Jasper Clube, to explore the possibility of using bacteria's own endogenous CRISPR-associated (Cas) proteins to cut its DNA, CEO Grøndahl told BioCentury...